ArticleOncogene2025
TRIM21-mediated ubiquitination of SIX2 attenuates breast cancer stemness via LGSN suppression.
Article in Oncogene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The role of e3 ubiquitin ligases and deubiquitinating enzymes in hepatocellular carcinoma.Cell biology and toxicology · 2026Review
- TRIM68 regulates ubiquitinated degradation of Rabex-5 and plays a role in progression of breast cancer through Rab5-Rac1.American journal of cancer research · 2026Article
- TRIM21 suppresses uterine corpus endometrial carcinoma progression by promoting K48 -linked ubiquitination and degradation of SOAT1.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Breast cancer stem cells (BCSCs) are pivotal drivers of breast tumor initiation, metastasis, and therapy resistance. Our previous studies identified the transcription factor SIX2 as a key regulator in maintaining breast cancer stemness. Here, we demonstrate that TRIM21, as an E3 ubiquitin ligase downregulated in breast cancer tissues, binds to SIX2 via its PRY-SPRY domain and catalyzes K48-type ubiquitination at lysine residues K82, K89, and K97. This modification promotes the degradation of SIX2 via the ubiquitin-proteasome pathway, consequently attenuating the stemness and metastatic potential of breast cancer cells. Furthermore, SIX2 transcriptionally activates LGSN expression through direct binding to its promoter region, thereby promoting the stemness and metastatic capabilities of breast cancer cells. Clinically, elevated expression of both SIX2 and LGSN correlates with poor prognosis in breast cancer patients. These results establish that TRIM21-mediated degradation of SIX2 suppresses LGSN expression, ultimately inhibiting the stemness and metastatic abilities of breast cancer cells, underscoring the critical regulatory role of the TRIM21-SIX2-LGSN axis in breast cancer progression.
Indexed as
Identifiers
40954199What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.